Automate Your Wheel Strategy on SPRO
With Tiblio's Option Bot, you can configure your own wheel strategy including SPRO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SPRO
- Rev/Share 0.6269
- Book/Share 0.6106
- PB 4.6674
- Debt/Equity 0.1171
- CurrentRatio 2.5626
- ROIC -1.4719
- MktCap 159345210.0
- FreeCF/Share -0.6029
- PFCF -4.7731
- PE -2.8234
- Debt/Assets 0.051
- DivYield 0
- ROE -0.9896
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SPRO | Evercore ISI | Outperform | In-line | -- | $5 | Dec. 20, 2024 |
News
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
Published: June 11, 2025 by: Seeking Alpha
Sentiment: Positive
Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a license partner, will take over commercialization. Approval is expected to trigger in total of $175 million in milestone payments over the next 12 months.
Read More
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
Read More
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
Published: May 28, 2025 by: Benzinga
Sentiment: Positive
GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.
Read More
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025.
Read More
About Spero Therapeutics, Inc. (SPRO)
- IPO Date 2017-11-02
- Website https://sperotherapeutics.com
- Industry Biotechnology
- CEO Ms. Esther P. Rajavelu
- Employees 32